Porous Starch: a Novel Carrier for Solubility Enhancement of Carbamazepine
- 610 Downloads
To circumvent the solubility-related issues associated with Biopharmaceutics Classification System class II drugs, a novel porous carrier has been developed. In the present study, a process for preparation of porous starch (PS) is demonstrated. The process briefly comprises of translucent gel preparation followed by solvent replacement, drying, and sizing. Carbamazepine (CBZ) was used as a drug candidate to exhibit solubility enhancement potential of PS. PS and CBZ-loaded PS (CBZ-PS) systems were characterized with respect to IR, DSC, XRD, SEM, and dissolution kinetic studies. PS-CBZ was found to follow a Fickian behavior during dissolution. In vivo studies conducted in mice displayed a superior performance of CBZ-PS as compared to neat CBZ.
KEY WORDScarbamazepine dissolution solubility enhancement
The authors would like to thank University Grants Commission, Government of India, for their financial support.
- 6.Murdande SB, Pikal MJ, Shanker RM, Bogner RH. Solubility advantage of amorphous pharmaceuticals: II. Application of quantitative thermodynamic relationships for prediction of solubility enhancement in structurally diverse insoluble pharmaceuticals. Pharm Res. 2010;27(12):2704–14.PubMedCrossRefGoogle Scholar
- 7.Meer TS, Sawant KP, Amin PD. Liquid anti solvent precipitation process for solubility modulation of bicalutamide. Acta Pharma. 2011;61(4):435–45.Google Scholar
- 8.Moffat AC, Osselton MD, Widdop Clarke B. Analysis of drugs and poisons, vol. II. London: Pharmaceutical Press; 2004. p. 747–49.Google Scholar
- 10.Achumecher GE. Therapeutic drug monitoring. New York: Appleton and Lange; 1995. p. 345–95.Google Scholar
- 15.Rowe RC, Shesky PJ, Quinn ME. Handbook of pharmaceutical excipients. 6th ed. London: Pharmaceutical Press; 2009. p. 685–90.Google Scholar
- 21.The United States Pharmacopeia (USP29). 29th ed. Rockville, MD: United States Pharmacopeial Convention Inc.; 2006.Google Scholar
- 29.Chan L, Caixia L, Yuan L, Jian-Feng C. Formation of bicalutamide nanodispersion for dissolution rate enhancement. Int J Pharm. 2011;404(1–2):257–63.Google Scholar
- 31.Clinckers R, Smolders I, Meurs A, Ebinger G, Michotte Y. Quantitative in vivo microdialysis study on the influence of multidrug transporters on the blood–brain barrier passage of oxcarbazepine: concomitant use of hippocampal monoamines as pharmacodynamic markers for the anticonvulsant activity. J Pharmacol Exp Ther. 2005;314(2):725–31.PubMedCrossRefGoogle Scholar